Literature DB >> 17141961

Erythropoietin-mediated preservation of the white matter in rat spinal cord injury.

L Vitellaro-Zuccarello1, S Mazzetti, L Madaschi, P Bosisio, A Gorio, S De Biasi.   

Abstract

We investigated the effect of a single administration of recombinant human erythropoietin (rhEPO) on the preservation of the ventral white matter of rats at 4 weeks after contusive spinal cord injury (SCI), a time at which functional recovery is significantly improved in comparison to the controls [Gorio A, Necati Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Enver Vardar E, Cerami A, Brines M (2002) Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 99:9450-9455; Gorio A, Madaschi L, Di Stefano B, Carelli S, Di Giulio AM, De Biasi S, Coleman T, Cerami A, Brines M (2005) Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci U S A 102:16379-16384]. Specifically, we examined, by morphological and cytochemical methods combined with light, confocal and electron microscopy, i) myelin preservation, ii) activation of adult oligodendrocyte progenitors (OPCs) identified for the expression of NG2 transmembrane proteoglycan, iii) changes in the amount of the chondroitin sulfate proteoglycans neurocan, versican and phosphacan and of their glycosaminoglycan component labeled with Wisteria floribunda lectin, and iv) ventral horn density of the serotonergic plexus as a marker of descending motor control axons. Injured rats received either saline or a single dose of rhEPO within 30 min after SCI. The results showed that the significant improvement of functional outcome observed in rhEPO-treated rats was associated with a better preservation of myelin in the ventral white matter. Moreover, the significant increase of both the number of NG2-positive OPCs and the labeling for Nogo-A, a marker of differentiated oligodendrocytes, suggested that rhEPO treatment could result in the generation of new myelinating oligodendrocytes. Sparing of fiber tracts in the ventral white matter was confirmed by the increased density of the serotonergic plexus around motor neurons. As for chondroitin sulfate proteoglycans, only phosphacan, increased in saline-treated rats, returned to normal levels in rhEPO group, probably reflecting a better maintenance of glial-axolemmal relationships along nerve fibers. In conclusion, this investigation expands previous studies supporting the pleiotropic neuroprotective effect of rhEPO on secondary degenerative response and its therapeutic potential for the treatment of SCI and confirms that the preservation of the ventral white matter, which contains descending motor pathways, may be critical for limiting functional deficit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141961     DOI: 10.1016/j.neuroscience.2006.10.023

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  24 in total

Review 1.  A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury.

Authors:  Brian K Kwon; Elena B Okon; Eve Tsai; Michael S Beattie; Jacqueline C Bresnahan; David K Magnuson; Paul J Reier; Dana M McTigue; Phillip G Popovich; Andrew R Blight; Martin Oudega; James D Guest; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-10-18       Impact factor: 5.269

2.  Cervical spinal erythropoietin induces phrenic motor facilitation via extracellular signal-regulated protein kinase and Akt signaling.

Authors:  Erica A Dale; Irawan Satriotomo; Gordon S Mitchell
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

3.  Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP).

Authors:  Davide Dalla Costa; Ettore Beghi; Paola Carignano; Cristina Pagliacci; Franco Faccioli; Elisabetta Pupillo; Paolo Messina; Alfredo Gorio; Tiziana Redaelli
Journal:  Neurol Sci       Date:  2015-03-28       Impact factor: 3.307

4.  Neuroprotection of erythropoietin and methylprednisolone against spinal cord ischemia-reperfusion injury.

Authors:  Min Xiong; Sen Chen; Hualong Yu; Zhigang Liu; Yun Zeng; Feng Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

Review 5.  A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury.

Authors:  Brian K Kwon; Elena Okon; Jessica Hillyer; Cody Mann; Darryl Baptiste; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-04-14       Impact factor: 5.269

6.  Erythropoietin amplifies stroke-induced oligodendrogenesis in the rat.

Authors:  Li Zhang; Michael Chopp; Rui Lan Zhang; Lei Wang; Jing Zhang; Ying Wang; Yier Toh; Manoranjan Santra; Mei Lu; Zheng Gang Zhang
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 7.  Role of erythropoietin in the brain.

Authors:  Constance Tom Noguchi; Pundit Asavaritikrai; Ruifeng Teng; Yi Jia
Journal:  Crit Rev Oncol Hematol       Date:  2007-05-04       Impact factor: 6.312

8.  A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury.

Authors:  Alberto Pinzon; Alexander Marcillo; Diego Pabon; Helen M Bramlett; Mary Bartlett Bunge; W Dalton Dietrich
Journal:  Exp Neurol       Date:  2008-07-14       Impact factor: 5.330

Review 9.  Erythropoietin in spinal cord injury.

Authors:  Georgios K Matis; Theodossios A Birbilis
Journal:  Eur Spine J       Date:  2008-11-22       Impact factor: 3.134

Review 10.  Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury.

Authors:  Shushi Kabu; Yue Gao; Brian K Kwon; Vinod Labhasetwar
Journal:  J Control Release       Date:  2015-09-04       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.